Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

IntraGel Therapeutics Secures $7M Investment From UroGen Pharma to Advance SRGel Platform and TumoCure Development.

PRIVATESep 01, 2026•7 days ago

Amount Raised

$7 Million

Round Type

Venture - Series Unknown

North DistrictBiotechnologyHealth CareTherapeutics

Investors

Uro Gen Pharma

Description

IntraGel Therapeutics, based in Nazareth, Israel, received a $7M investment from UroGen Pharma. The funding will be used to advance their SRGel platform and accelerate the clinical development of TumoCure. This investment supports the company's efforts in localized drug delivery technology. The lead product candidate, TumoCure, is Phase 2 ready for treating locally advanced, inoperable head and neck cancers.

Company Information

Company

IntraGel Therapeutics

Location

North District, Israel

About

IntraGel Therapeutics, Ltd. is a biotechnology company based in Nazareth, Israel that specializes in developing sustained-release formulation technology for localized drug delivery. Their proprietary SRGel platform enables controlled and prolonged local release of therapeutic agents directly within solid tumors while minimizing systemic exposure. The lead product candidate, TumoCure, is currently Phase 2-ready for treating locally advanced, inoperable head and neck cancers.

Don't miss IntraGel Therapeutics's next move

Get an email the moment IntraGel Therapeutics raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for IntraGel Therapeutics's next move

See what Strategic adds

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

IntraGel Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.